Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 332

1.

Machine Learning helps Identify New Drug Mechanisms in Triple-Negative Breast Cancer.

Athreya AP, Gaglio AJ, Cairns J, Kalari KR, Weinshilboum RM, Wang L, Kalbarczyk ZT, Iyer RK.

IEEE Trans Nanobioscience. 2018 Jul 2. doi: 10.1109/TNB.2018.2851997. [Epub ahead of print]

PMID:
29994716
2.

Single Nucleotide Polymorphisms (SNPs) Distant from Xenobiotic Response Elements Can Modulate Aryl Hydrocarbon Receptor Function: SNP-Dependent CYP1A1 Induction.

Liu D, Qin S, Ray B, Kalari KR, Wang L, Weinshilboum RM.

Drug Metab Dispos. 2018 Jul 6. pii: dmd.118.082164. doi: 10.1124/dmd.118.082164. [Epub ahead of print]

PMID:
29980579
3.

Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disorders.

Ahmed AT, Frye MA, Rush AJ, Biernacka JM, Craighead WE, McDonald WM, Bobo WV, Riva-Posse P, Tye SJ, Mayberg HS, Hall-Flavin DK, Skime MK, Jenkins GD, Wang L, Krishnan RR, Weinshilboum RM, Kaddurah-Daouk R, Dunlop BW; Mood Disorders Precision Medicine Consortium (MDPMC).

J Affect Disord. 2018 May 26;238:1-7. doi: 10.1016/j.jad.2018.05.005. [Epub ahead of print]

PMID:
29807322
4.

BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.

Fasching PA, Loibl S, Hu C, Hart SN, Shimelis H, Moore R, Schem C, Tesch H, Untch M, Hilfrich J, Rezai M, Gerber B, Costa SD, Blohmer JU, Fehm T, Huober J, Liedtke C, Weinshilboum RM, Wang L, Ingle JN, Müller V, Nekljudova V, Weber KE, Rack B, Rübner M, von Minckwitz G, Couch FJ.

J Clin Oncol. 2018 May 23:JCO2017772285. doi: 10.1200/JCO.2017.77.2285. [Epub ahead of print]

PMID:
29791287
5.

Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab.

Ingle JN, Kalari KR, Wickerham DL, von Minckwitz G, Fasching PA, Furukawa Y, Mushiroda T, Goetz MP, Barman P, Carlson EE, Rastogi P, Costantino JP, Cairns J, Paik S, Bear HD, Kubo M, Wang L, Wolmark N, Weinshilboum RM.

Pharmacogenet Genomics. 2018 Jun;28(6):147-152. doi: 10.1097/FPC.0000000000000337.

PMID:
29768301
6.

SLCO1B1 genetic variation and hormone therapy in menopausal women.

Moyer AM, de Andrade M, Faubion SS, Kapoor E, Dudenkov T, Weinshilboum RM, Miller VM.

Menopause. 2018 May 7. doi: 10.1097/GME.0000000000001109. [Epub ahead of print]

PMID:
29738412
7.

Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression.

Ho MF, Correia C, Ingle JN, Kaddurah-Daouk R, Wang L, Kaufmann SH, Weinshilboum RM.

Biochem Pharmacol. 2018 Jun;152:279-292. doi: 10.1016/j.bcp.2018.03.032. Epub 2018 Apr 3.

PMID:
29621538
8.

Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients.

Bidadi B, Liu D, Kalari KR, Rubner M, Hein A, Beckmann MW, Rack B, Janni W, Fasching PA, Weinshilboum RM, Wang L.

Front Pharmacol. 2018 Mar 13;9:158. doi: 10.3389/fphar.2018.00158. eCollection 2018.

9.

TCL1A, a Novel Transcription Factor and a Coregulator of Nuclear Factor κB p65: Single Nucleotide Polymorphism and Estrogen Dependence.

Ho MF, Lummertz da Rocha E, Zhang C, Ingle JN, Goss PE, Shepherd LE, Kubo M, Wang L, Li H, Weinshilboum RM.

J Pharmacol Exp Ther. 2018 Jun;365(3):700-710. doi: 10.1124/jpet.118.247718. Epub 2018 Mar 28.

PMID:
29592948
10.

Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder.

Amare AT, Schubert KO, Tekola-Ayele F, Hsu YH, Sangkuhl K, Jenkins G, Whaley RM, Barman P, Batzler A, Altman RB, Arolt V, Brockmöller J, Chen CH, Domschke K, Hall-Flavin DK, Hong CJ, Illi A, Ji Y, Kampman O, Kinoshita T, Leinonen E, Liou YJ, Mushiroda T, Nonen S, Skime MK, Wang L, Kato M, Liu YL, Praphanphoj V, Stingl JC, Bobo WV, Tsai SJ, Kubo M, Klein TE, Weinshilboum RM, Biernacka JM, Baune BT.

Front Psychiatry. 2018 Mar 6;9:65. doi: 10.3389/fpsyt.2018.00065. eCollection 2018.

11.

Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics.

Liu D, Ray B, Neavin DR, Zhang J, Athreya AP, Biernacka JM, Bobo WV, Hall-Flavin DK, Skime MK, Zhu H, Jenkins GD, Batzler A, Kalari KR, Boakye-Agyeman F, Matson WR, Bhasin SS, Mushiroda T, Nakamura Y, Kubo M, Iyer RK, Wang L, Frye MA, Kaddurah-Daouk R, Weinshilboum RM.

Transl Psychiatry. 2018 Jan 10;8(1):10. doi: 10.1038/s41398-017-0056-8.

12.

Considerations for automated machine learning in clinical metabolic profiling: Altered homocysteine plasma concentration associated with metformin exposure.

Orlenko A, Moore JH, Orzechowski P, Olson RS, Cairns J, Caraballo PJ, Weinshilboum RM, Wang L, Breitenstein MK.

Pac Symp Biocomput. 2018;23:460-471.

13.

New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation.

Fabbri C, Tansey KE, Perlis RH, Hauser J, Henigsberg N, Maier W, Mors O, Placentino A, Rietschel M, Souery D, Breen G, Curtis C, Sang-Hyuk L, Newhouse S, Patel H, Guipponi M, Perroud N, Bondolfi G, O'Donovan M, Lewis G, Biernacka JM, Weinshilboum RM, Farmer A, Aitchison KJ, Craig I, McGuffin P, Uher R, Lewis CM.

Pharmacogenomics J. 2018 May 22;18(3):413-421. doi: 10.1038/tpj.2017.44. Epub 2017 Nov 21.

PMID:
29160301
14.

Pharmacogenomics: Precision Medicine and Drug Response.

Weinshilboum RM, Wang L.

Mayo Clin Proc. 2017 Nov;92(11):1711-1722. doi: 10.1016/j.mayocp.2017.09.001. Epub 2017 Nov 1. Review.

PMID:
29101939
15.

Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity.

Fasching PA, Häberle L, Rack B, Li L, Hein A, Ekici AB, Reis A, Lux MP, Cunningham JM, Ruebner M, Jenkins G, Fridley B, Schneeweiss A, Tesch H, Lichtenegger W, Fehm T, Heinrich G, Rezai M, Beckmann MW, Janni W, Weinshilboum RM, Wang L.

Oncotarget. 2017 May 9;8(44):78133-78143. doi: 10.18632/oncotarget.17726. eCollection 2017 Sep 29.

16.

A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone.

Wang L, Dehm SM, Hillman DW, Sicotte H, Tan W, Gormley M, Bhargava V, Jimenez R, Xie F, Yin P, Qin S, Quevedo F, Costello BA, Pitot HC, Ho T, Bryce AH, Ye Z, Li Y, Eiken P, Vedell PT, Barman P, McMenomy BP, Atwell TD, Carlson RE, Ellingson M, Eckloff BW, Qin R, Ou F, Hart SN, Huang H, Jen J, Wieben ED, Kalari KR, Weinshilboum RM, Wang L, Kohli M.

Ann Oncol. 2018 Feb 1;29(2):352-360. doi: 10.1093/annonc/mdx689.

PMID:
29069303
17.

TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer.

Qin S, Liu D, Kohli M, Wang L, Vedell PT, Hillman DW, Niu N, Yu J, Weinshilboum RM, Wang L.

Clin Pharmacol Ther. 2018 Jul;104(1):201-210. doi: 10.1002/cpt.907. Epub 2017 Nov 22.

18.
19.

Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes.

Liu D, Ho MF, Schaid DJ, Scherer SE, Kalari K, Liu M, Biernacka J, Yee V, Evans J, Carlson E, Goetz MP, Kubo M, Wickerham DL, Wang L, Ingle JN, Weinshilboum RM.

NPJ Breast Cancer. 2017 Aug 21;3:30. doi: 10.1038/s41523-017-0036-4. eCollection 2017.

20.

Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion.

Qin S, Ingle JN, Liu M, Yu J, Wickerham DL, Kubo M, Weinshilboum RM, Wang L.

Breast Cancer Res. 2017 Aug 18;19(1):95. doi: 10.1186/s13058-017-0890-x.

21.

Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study.

Hein A, Rack B, Li L, Ekici AB, Reis A, Lux MP, Cunningham JM, Rübner M, Fridley BL, Schneeweiss A, Tesch H, Lichtenegger W, Fehm T, Heinrich G, Rezai M, Beckmann MW, Janni W, Weinshilboum RM, Wang L, Fasching PA, Häberle L.

Geburtshilfe Frauenheilkd. 2017 Jun;77(6):651-659. doi: 10.1055/s-0042-113189. Epub 2017 Jun 28.

22.

TCL1A Single-Nucleotide Polymorphisms and Estrogen-Mediated Toll-Like Receptor-MYD88-Dependent Nuclear Factor-κB Activation: Single-Nucleotide Polymorphism- and Selective Estrogen Receptor Modulator-Dependent Modification of Inflammation and Immune Response.

Ho MF, Ingle JN, Bongartz T, Kalari KR, Goss PE, Shepherd LE, Mushiroda T, Kubo M, Wang L, Weinshilboum RM.

Mol Pharmacol. 2017 Aug;92(2):175-184. doi: 10.1124/mol.117.108340. Epub 2017 Jun 14.

PMID:
28615284
23.

SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway.

Dudenkov TM, Ingle JN, Buzdar AU, Robson ME, Kubo M, Ibrahim-Zada I, Batzler A, Jenkins GD, Pietrzak TL, Carlson EE, Barman P, Goetz MP, Northfelt DW, Moreno-Aspita A, Williard CV, Kalari KR, Nakamura Y, Wang L, Weinshilboum RM.

Breast Cancer Res Treat. 2017 Jul;164(1):189-199. doi: 10.1007/s10549-017-4243-3. Epub 2017 Apr 20.

24.

Electronic Medical Record-Integrated Pharmacogenomics and Related Clinical Decision Support Concepts.

Caraballo PJ, Bielinski SJ, St Sauver JL, Weinshilboum RM.

Clin Pharmacol Ther. 2017 Aug;102(2):254-264. doi: 10.1002/cpt.707. Epub 2017 May 26. Review.

PMID:
28390138
25.

The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems.

Luzum JA, Pakyz RE, Elsey AR, Haidar CE, Peterson JF, Whirl-Carrillo M, Handelman SK, Palmer K, Pulley JM, Beller M, Schildcrout JS, Field JR, Weitzel KW, Cooper-DeHoff RM, Cavallari LH, O'Donnell PH, Altman RB, Pereira N, Ratain MJ, Roden DM, Embi PJ, Sadee W, Klein TE, Johnson JA, Relling MV, Wang L, Weinshilboum RM, Shuldiner AR, Freimuth RR; Pharmacogenomics Research Network Translational Pharmacogenetics Program.

Clin Pharmacol Ther. 2017 Sep;102(3):502-510. doi: 10.1002/cpt.630. Epub 2017 Jun 9.

PMID:
28090649
26.

Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine.

Giacomini KM, Yee SW, Mushiroda T, Weinshilboum RM, Ratain MJ, Kubo M.

Nat Rev Drug Discov. 2017 Jan;16(1):1. doi: 10.1038/nrd.2016.234. Epub 2016 Nov 25. No abstract available.

27.

Are patients willing to incur out-of-pocket costs for pharmacogenomic testing?

Bielinski SJ, St Sauver JL, Olson JE, Wieland ML, Vitek CR, Bell EJ, Mc Gree ME, Jacobson DJ, McCormick JB, Takahashi PY, Black JL, Caraballo PJ, Sharp RR, Beebe TJ, Weinshilboum RM, Wang L, Roger VL.

Pharmacogenomics J. 2017 Jan;17(1):1-3. doi: 10.1038/tpj.2016.72. Epub 2016 Oct 25. No abstract available.

28.

Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy.

Ingle JN, Xie F, Ellis MJ, Goss PE, Shepherd LE, Chapman JW, Chen BE, Kubo M, Furukawa Y, Momozawa Y, Stearns V, Pritchard KI, Barman P, Carlson EE, Goetz MP, Weinshilboum RM, Kalari KR, Wang L.

Cancer Res. 2016 Dec 1;76(23):7012-7023. Epub 2016 Oct 10.

29.

Multidisciplinary model to implement pharmacogenomics at the point of care.

Caraballo PJ, Hodge LS, Bielinski SJ, Stewart AK, Farrugia G, Schultz CG, Rohrer-Vitek CR, Olson JE, St Sauver JL, Roger VL, Parkulo MA, Kullo IJ, Nicholson WT, Elliott MA, Black JL, Weinshilboum RM.

Genet Med. 2017 Apr;19(4):421-429. doi: 10.1038/gim.2016.120. Epub 2016 Sep 22.

30.

Influence of SULT1A1 genetic variation on age at menopause, estrogen levels, and response to hormone therapy in recently postmenopausal white women.

Moyer AM, de Andrade M, Weinshilboum RM, Miller VM.

Menopause. 2016 Aug;23(8):863-9. doi: 10.1097/GME.0000000000000648.

31.

Genomewide Association Studies in Pharmacogenomics: Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration.

Yee SW, Momozawa Y, Kamatani Y, Tyndale RF, Weinshilboum RM, Ratain MJ, Giacomini KM, Kubo M.

Clin Pharmacol Ther. 2016 Nov;100(5):423-426. doi: 10.1002/cpt.405. Epub 2016 Jul 21.

32.

Combined Effects of Acamprosate and Escitalopram on Ethanol Consumption in Mice.

Ho AM, Qiu Y, Jia YF, Aguiar FS, Hinton DJ, Karpyak VM, Weinshilboum RM, Choi DS.

Alcohol Clin Exp Res. 2016 Jul;40(7):1531-9. doi: 10.1111/acer.13099. Epub 2016 May 17.

33.

Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade.

Ji Y, Skierka JM, Blommel JH, Moore BE, VanCuyk DL, Bruflat JK, Peterson LM, Veldhuizen TL, Fadra N, Peterson SE, Lagerstedt SA, Train LJ, Baudhuin LM, Klee EW, Ferber MJ, Bielinski SJ, Caraballo PJ, Weinshilboum RM, Black JL 3rd.

J Mol Diagn. 2016 May;18(3):438-445. doi: 10.1016/j.jmoldx.2016.01.003. Epub 2016 Mar 3.

34.

TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics.

Gupta M, Neavin D, Liu D, Biernacka J, Hall-Flavin D, Bobo WV, Frye MA, Skime M, Jenkins GD, Batzler A, Kalari K, Matson W, Bhasin SS, Zhu H, Mushiroda T, Nakamura Y, Kubo M, Wang L, Kaddurah-Daouk R, Weinshilboum RM.

Mol Psychiatry. 2016 Dec;21(12):1717-1725. doi: 10.1038/mp.2016.6. Epub 2016 Feb 23.

35.

Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation.

Ho MF, Bongartz T, Liu M, Kalari KR, Goss PE, Shepherd LE, Goetz MP, Kubo M, Ingle JN, Wang L, Weinshilboum RM.

Mol Endocrinol. 2016 Mar;30(3):382-98. doi: 10.1210/me.2015-1267. Epub 2016 Feb 11.

36.

Electrophysiological Neuroimaging using sLORETA Comparing 22 Age Matched Male and Female Schizophrenia Patients.

Eugene AR, Masiak J, Kapica J, Masiak M, Weinshilboum RM.

Hosp Chron. 2015;10(2):91-98.

37.

Leveraging an Electronic Health Record-Linked Biorepository to Generate a Metformin Pharmacogenomics Hypothesis.

Breitenstein MK, Wang L, Simon G, Ryu E, Armasu SM, Ray B, Weinshilboum RM, Pathak J.

AMIA Jt Summits Transl Sci Proc. 2015 Mar 23;2015:26-30. eCollection 2015.

38.

Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects.

Nam HW, Karpyak VM, Hinton DJ, Geske JR, Ho AM, Prieto ML, Biernacka JM, Frye MA, Weinshilboum RM, Choi DS.

Transl Psychiatry. 2015 Aug 18;5:e621. doi: 10.1038/tp.2015.120.

39.

Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study.

Hein A, Lambrechts D, von Minckwitz G, Häberle L, Eidtmann H, Tesch H, Untch M, Hilfrich J, Schem C, Rezai M, Gerber B, Dan Costa S, Blohmer JU, Schwedler K, Kittel K, Fehm T, Kunz G, Beckmann MW, Ekici AB, Hanusch C, Huober J, Liedtke C, Mau C, Moisse M, Müller V, Nekljudova V, Peuteman G, Rack B, Rübner M, Van Brussel T, Wang L, Weinshilboum RM, Loibl S, Fasching PA.

Int J Cancer. 2015 Dec 15;137(12):2981-8. doi: 10.1002/ijc.29656. Epub 2015 Jul 6.

40.

Using EHR-Linked Biobank Data to Study Metformin Pharmacogenomics.

Breitenstein MK, Simon G, Ryu E, Armasu SM, Weinshilboum RM, Wang L, Pathak J.

Stud Health Technol Inform. 2015;210:914-8.

41.

Accuracy of Electronic Medical Record Medication Reconciliation in Emergency Department Patients.

Monte AA, Anderson P, Hoppe JA, Weinshilboum RM, Vasiliou V, Heard KJ.

J Emerg Med. 2015 Jul;49(1):78-84. doi: 10.1016/j.jemermed.2014.12.052. Epub 2015 Mar 19.

42.

Circulating atrial natriuretic peptide genetic association study identifies a novel gene cluster associated with stroke in whites.

Pereira NL, Tosakulwong N, Scott CG, Jenkins GD, Prodduturi N, Chai Y, Olson TM, Rodeheffer RJ, Redfield MM, Weinshilboum RM, Burnett JC.

Circ Cardiovasc Genet. 2015 Feb;8(1):141-9. doi: 10.1161/CIRCGENETICS.114.000624. Epub 2014 Dec 1.

43.

The eSNV-detect: a computational system to identify expressed single nucleotide variants from transcriptome sequencing data.

Tang X, Baheti S, Shameer K, Thompson KJ, Wills Q, Niu N, Holcomb IN, Boutet SC, Ramakrishnan R, Kachergus JM, Kocher JP, Weinshilboum RM, Wang L, Thompson EA, Kalari KR.

Nucleic Acids Res. 2014 Dec 16;42(22):e172. doi: 10.1093/nar/gku1005. Epub 2014 Oct 28.

44.

Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.

Levinsen M, Rosthøj S, Nygaard U, Heldrup J, Harila-Saari A, Jonsson OG, Bechensteen AG, Abrahamsson J, Lausen B, Frandsen TL, Weinshilboum RM, Schmiegelow K.

Cancer Chemother Pharmacol. 2015 Jan;75(1):59-66. doi: 10.1007/s00280-014-2613-7. Epub 2014 Oct 28.

45.

Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate.

Karpyak VM, Biernacka JM, Geske JR, Jenkins GD, Cunningham JM, Rüegg J, Kononenko O, Leontovich AA, Abulseoud OA, Hall-Flavin DK, Loukianova LL, Schneekloth TD, Skime MK, Frank J, Nöthen MM, Rietschel M, Kiefer F, Mann KF, Weinshilboum RM, Frye MA, Choi DS.

Transl Psychiatry. 2014 Oct 7;4:e462. doi: 10.1038/tp.2014.103.

46.

Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole.

Ingle JN, Kalari KR, Buzdar AU, Robson ME, Goetz MP, Desta Z, Barman P, Dudenkov TT, Northfelt DW, Perez EA, Flockhart DA, Williard CV, Wang L, Weinshilboum RM.

Steroids. 2015 Jul;99(Pt A):32-8. doi: 10.1016/j.steroids.2014.08.007. Epub 2014 Aug 24.

47.

The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness.

Monte AA, Heard KJ, Campbell J, Hamamura D, Weinshilboum RM, Vasiliou V.

Acad Emerg Med. 2014 Aug;21(8):879-85. doi: 10.1111/acem.12431. Epub 2014 Aug 24.

48.

Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics.

Liu M, Goss PE, Ingle JN, Kubo M, Furukawa Y, Batzler A, Jenkins GD, Carlson EE, Nakamura Y, Schaid DJ, Chapman JA, Shepherd LE, Ellis MJ, Khosla S, Wang L, Weinshilboum RM.

Mol Endocrinol. 2014 Oct;28(10):1740-51. doi: 10.1210/me.2014-1147. Epub 2014 Aug 22.

49.

Inflammation-related genetic variants predict toxicity following definitive radiotherapy for lung cancer.

Pu X, Wang L, Chang JY, Hildebrandt MA, Ye Y, Lu C, Skinner HD, Niu N, Jenkins GD, Komaki R, Minna JD, Roth JA, Weinshilboum RM, Wu X.

Clin Pharmacol Ther. 2014 Nov;96(5):609-15. doi: 10.1038/clpt.2014.154. Epub 2014 Jul 23.

50.

Genotype-guided dosing of vitamin K antagonists.

Pereira NL, Rihal CS, Weinshilboum RM.

N Engl J Med. 2014 May 1;370(18):1762. doi: 10.1056/NEJMc1402521. No abstract available.

PMID:
24785216

Supplemental Content

Loading ...
Support Center